Navigation Links
Dendreon Initiates Phase 2 Trial of PROVENGE in Patients With Localized Prostate Cancer Prior to Surgery
Date:7/16/2008

actual prostate cancer tissue and to examine the correlation between immune responses in the tissue versus those in the circulating blood."

"Given the evidence of a survival benefit seen in our previous Phase 3 trial, D9901, in patients with advanced prostate cancer, we believe PROVENGE may also have applicability to men with earlier stages of the disease. This trial will help us better understand the mechanism of action and biology of PROVENGE, as well as evaluate the potential of PROVENGE in patients at high-risk for recurrence of their cancer following radical prostatectomy," stated Mark Frohlich, M.D., senior vice president, clinical affairs and chief medical officer of Dendreon. "We are highly focused on taking the steps necessary to get PROVENGE through the FDA approval process in order to get this important immunotherapy to prostate cancer patients with advanced disease who do not have any other reasonable options. We are on track to complete the interim analysis of our ongoing Phase 3 IMPACT trial during the latter half of this year."

About Prostate Cancer

Prostate cancer is the most common non-skin cancer in the United States and the third most common cancer worldwide. More than one million men in the United States have prostate cancer, with an estimated 186,320 new cases expected to be diagnosed in 2008, and approximately 28,660 men expected to die this year from the disease. Currently there are limited treatment options for men with advanced, metastatic prostate cancer.

About Active Cellular Immunotherapy with PROVENGE

PROVENGE may represent the first product in a new class of active cellular immunotherapies (ACIs) that are uniquely designed to use live human cells to engage the patient's own immune system with the goal of eliciting a specific long-lasting response against cancer. Active cellular immunotherapy holds promise because it may provide patients with a meaningful clinical benefit, such as survival, combined wit
'/>"/>

SOURCE Dendreon Corporation
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine technology :

1. Dendreon Presents Preclinical Data Demonstrating Activity of Trp-p8 agonist, D-3263, in Benign Prostatic Hyperplasia
2. Dendreon Presents Data Correlating the Cumulative Potency of PROVENGE(R) to Overall Survival
3. Dendreon Completes Target Enrollment of 500 Patients in Phase 3 IMPACT Study of Provenge(R) For Advanced Prostate Cancer
4. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
5. Rib-X Pharmaceuticals Initiates Phase 2 Trial for RX-3341 In Complicated Skin and Skin Structure Infections
6. MAP Pharmaceuticals Initiates Phase 3 Clinical Trial in Patients With Migraine
7. NeurogesX Initiates Dosing in Phase 1 Clinical Trial for NGX-1998 Capsaicin Liquid Formulation
8. Proteolix Initiates Phase 1b Clinical Trial of Carfilzomib in a Combination Regimen for Patients With Relapsed Multiple Myeloma
9. Cerimon Pharmaceuticals Initiates Phase II Study to Evaluate Simulect(R) (Basiliximab) for Noninfectious Uveitis
10. Orexigen(R) Initiates Second Phase IIb Empatic(TM) Trial on Schedule
11. Echo Therapeutics Initiates Clinical Study of Its Symphony(TM) Transdermal Continuous Glucose Monitoring System in Patients with Type 1 and Type 2 Diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/9/2008)...s and Marketing Efforts to Accelerate ... PARK, Calif., Oct. 9 /- Evalve, Inc.... percutaneous repair of cardiac valves,has expand... appointment of,Sean Cleary as senior vice preside...ardson, as vice president of sales., "The additio...
(Date:10/9/2008)...FirstCall/ -- Diamyd Medical reports,that the worl...and Journal,of Medicine, has published an article ...d(R) diabetes vaccine for type 1 diabetes., (Logo...7194 ), The article is now available on the jour... in print on October 30. It presents the,results o...
(Date:10/8/2008)...atments for Spinal Cord, Other Nerve,Injuries -, ...protein that enables,nerve cells to communicate wi...developing nervous system. Research into how that ...rve cells may provide a basis for eventual,treatme...ous system,including spinal cord injury., "This ...
(Date:10/8/2008)...sts Expand Testing Using Cellular ..., Oct. 8 /- Wild Blueberry antioxidan...lts from a new study,showing Wild Blueberries outp...ke apples, bananas, red grapes and strawberries in...ctivity (CAA) assay. New research,published in the...
Breaking Medicine Technology:Evalve Expands Executive Leadership Team 2Evalve Expands Executive Leadership Team 3Diamyd(R) Study Published in Prestigious New England Journal of Medicine 2Diamyd(R) Study Published in Prestigious New England Journal of Medicine 3Diamyd(R) Study Published in Prestigious New England Journal of Medicine 4Protein Shown to Play a Key Role in Normal Development of Nervous System 2Protein Shown to Play a Key Role in Normal Development of Nervous System 3Wild Blueberries Take Top Spot in New Antioxidant Research Study 2Wild Blueberries Take Top Spot in New Antioxidant Research Study 3SportCoatings 3B The North American Booster Club Association 28NABCA 29 3B the Coatings Specialist Group New Booster Program Goes High Tech With Invi 149 1SportCoatings 3B The North American Booster Club Association 28NABCA 29 3B the Coatings Specialist Group New Booster Program Goes High Tech With Invi 149 2SportCoatings 3B The North American Booster Club Association 28NABCA 29 3B the Coatings Specialist Group New Booster Program Goes High Tech With Invi 149 3Weight Loss Surgeries Extend Lives 152 1Weight Loss Surgeries Extend Lives 152 2Weight Loss Surgeries Extend Lives 152 3Weight Loss Surgeries Extend Lives 152 4NYC area 1st 3A Morgan Stanley Childrens Hospital performs transcatheter pulmonary valve replacement 150 1NYC area 1st 3A Morgan Stanley Childrens Hospital performs transcatheter pulmonary valve replacement 150 2Restless legs syndrome affects nearly 2 percent of US UK children 135 1Restless legs syndrome affects nearly 2 percent of US UK children 135 2Restless legs syndrome affects nearly 2 percent of US UK children 135 3
... release broad range of clinical data on leading,d..., 2007 /PRNewswire-FirstCall/ -- Boston,Scientific...ompany,s major events and press announcements at t...CR), which will runs from May 22,to 25 in Barcelon...everal of our clinical,trials and registries, addi...
..., Calif.--(BUSINESS WIRE)--May 15, 2007 - Syntheti...ounced positive data from,a statistical analysis o... with traumatic brain injury. In line with prelimi...tistical results,confirmed that the primary endpoi...ompared with baseline was met. Data also show a,de...
Other Medicine Technology:Boston Scientific Announces Schedule for EuroPcr 2007 2Boston Scientific Announces Schedule for EuroPcr 2007 3Boston Scientific Announces Schedule for EuroPcr 2007 4Boston Scientific Announces Schedule for EuroPcr 2007 5Positive Statistical Analysis from Synthetic Blood's Oxycyte,Traumatic Brain Injury Trial Indicates Achievement of Primary,Endpoint 2Positive Statistical Analysis from Synthetic Blood's Oxycyte,Traumatic Brain Injury Trial Indicates Achievement of Primary,Endpoint 3
(Date:10/14/2008)... Also debuts TMR,09 campaign, IRVINE, Calif., O...poration (Pink Sheets: CGCP), a global leader of i...nd the market leader of surgical products for,tran...educational symposium,yesterday in conjunction wit...rapeutics (TCT) meeting in Washington, D.C., The ...
(Date:10/14/2008)... more than 500 accounts Company opening new PROMUS...ICK, Mass., Oct. 14 /PRNewswire-FirstCall/ -- Bost...unced estimated U.S. market shares for,September f...liminary data,from Millennium Research Group (MRG)...he healthcare sector., Based on the MRG data, the...
(Date:10/14/2008)... Leading Supplemental Insurance Company Encour... Employee Benefits , Chic...e , a leading provider of supplemental insurance, ...time to review employee benefits and recommends ,V...to help retain employees. These programs can be a ...
(Date:10/14/2008)...ctober 14 /PRNewswire/ -- Researchers at the Insti... started work on a 3.5 year,project to develop a n...hemical vapour deposition) diamond manufactured by...he field of CVD diamond synthesis and its,applicat...uld open up a raft of new,application areas in, fo...
Breaking Medicine News(10 mins):Health News:Cardiogenesis Announces Successful Educational Symposium Targeted at Cardiologists at the TCT Meeting in Washington, D.C. 2Health News:Cardiogenesis Announces Successful Educational Symposium Targeted at Cardiologists at the TCT Meeting in Washington, D.C. 3Health News:Cardiogenesis Announces Successful Educational Symposium Targeted at Cardiologists at the TCT Meeting in Washington, D.C. 4Health News:Boston Scientific Announces Drug-Eluting Stent Market Share Estimates for September and Third Quarter 2Health News:Boston Scientific Announces Drug-Eluting Stent Market Share Estimates for September and Third Quarter 3Health News:Boston Scientific Announces Drug-Eluting Stent Market Share Estimates for September and Third Quarter 4Health News:Combined Insurance Reports that Voluntary Programs Can Offer Employers a Cost Effective Way to Offer Benefits and Help Retain Employees 2Health News:Combined Insurance Reports that Voluntary Programs Can Offer Employers a Cost Effective Way to Offer Benefits and Help Retain Employees 3Health News:Combined Insurance Reports that Voluntary Programs Can Offer Employers a Cost Effective Way to Offer Benefits and Help Retain Employees 4Health News:Combined Insurance Reports that Voluntary Programs Can Offer Employers a Cost Effective Way to Offer Benefits and Help Retain Employees 5Health News:Novel Solid-State Laser Design Based on Synthetic Diamond From Element Six Opens up New Applications 2Health News:Novel Solid-State Laser Design Based on Synthetic Diamond From Element Six Opens up New Applications 3Health News:Novel Solid-State Laser Design Based on Synthetic Diamond From Element Six Opens up New Applications 4
...ed the G8 summit of the world's top industrialised..., warning that inaction would be costly. In a st...mm in Germany, Ban said the eight participating na... long-term global framework to tackle climate chan...
... womens insecurity about their body and their body...J. They believe that women should be warned about...lternative solutions to concerns about the appeara...hould be developed. More and more women are said ...
...s regularly investigated and debated for its impac... disease. Among its complex effects on the body, c... insulin and uric acid levels on a short-term basi...s suggest that coffee consumption may affect the r...
...ely low frequency electromagnetic fields, suggests...l and Environmental Medicine. The findings are ba... were monitored for 30 years. The researchers opt..., because railway workers in Switzerland tend to c...
Other Medicine News:Health News:Cosmetic Genital Surgery may Be Fuelling Womens Insecurity About Their Bodies 2Health News:Four Cups of Coffee a Day may Cut Down the Risk of Gout 2Health News:Four Cups of Coffee a Day may Cut Down the Risk of Gout 3
...aSuite EHR is designed to improve the efficiency a...n the ability to capture and recall patient inform... formats. As an electronic health record applicati...terface and is compatible with all Microsoft Offic...
Dairylands Clinical Information Management solutions provide organizations a suite of integrated applications that span all clinical departments and automate administrative and clinical documentation
Our electronic charts include a Patient Face Sheet, summarizing patient information and as many as six custom tabs, so you can customize which information is important for you to document. In additio
ChartKeeper 5 is Windows-based and shares functionality with other Microsoft programs. Since ChartKeeper 5 also uses Microsoft Word as the embedded text editor you have the functionality of MS Word f
Medicine Products: